双特异性抗体疗法

预约门诊
打印

科室与专家门诊

妙佑医疗国际是美国规模最大、经验最丰富的医疗机构之一，在亚利桑那州、佛罗里达州和明尼苏达州都设有院区。我们的工作人员涉及数十种专业，通过齐心协力确保高品质治疗与成功康复。

有相关专长的科室

行此手术的医生

编辑搜索过滤条件
close

缩小搜索范围

  1. 查找姓氏以该字母开头的医生 A
  2. 查找姓氏以该字母开头的医生 B
  3. 查找姓氏以该字母开头的医生 C
  4. 未找到姓氏以该字母开头的医生 D
  5. 未找到姓氏以该字母开头的医生 E
  6. 未找到姓氏以该字母开头的医生 F
  7. 未找到姓氏以该字母开头的医生 G
  8. 未找到姓氏以该字母开头的医生 H
  9. 未找到姓氏以该字母开头的医生 I
  10. 未找到姓氏以该字母开头的医生 J
  11. 查找姓氏以该字母开头的医生 K
  12. 未找到姓氏以该字母开头的医生 L
  13. 未找到姓氏以该字母开头的医生 M
  14. 未找到姓氏以该字母开头的医生 N
  15. 未找到姓氏以该字母开头的医生 O
  16. 未找到姓氏以该字母开头的医生 P
  17. 未找到姓氏以该字母开头的医生 Q
  18. 未找到姓氏以该字母开头的医生 R
  19. 查找姓氏以该字母开头的医生 S
  20. 未找到姓氏以该字母开头的医生 T
  21. 未找到姓氏以该字母开头的医生 U
  22. 查找姓氏以该字母开头的医生 V
  23. 未找到姓氏以该字母开头的医生 W
  24. 未找到姓氏以该字母开头的医生 X
  25. 未找到姓氏以该字母开头的医生 Y
  26. 查找姓氏以该字母开头的医生 Z
重置所有过滤器

显示$起始范围 - $结束范围/源自可用$可用医生

  1. Stephen M. Ansell, M.D., Ph.D.

    Stephen M. Ansell, M.D., Ph.D.

    1. Internist
    2. Oncologist
    3. Hematologist
    1. Rochester, MN
    擅长领域：

    CAR-T cell therapy, Bispecific antibody therapy, Non-Hodgkin lymphoma, Hodgkin lymphoma, B-cell lymphoma, Burkitt lymph...oma, Follicular lymphoma, Peripheral T-cell lymphoma, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue

  2. Tanios S. Bekaii-Saab, M.D.

    Tanios S. Bekaii-Saab, M.D.

    1. Oncologist
    1. Phoenix, AZ
    擅长领域：

    Bispecific antibody therapy, Chemotherapy for colon cancer, Colon cancer, Liver cancer, Pancreatic cancer, Neuroendocri...ne tumor, Rectal cancer, Stomach cancer, Cholangiocarcinoma, Esophageal cancer, Gallbladder cancer, Anal cancer, Gastrointestinal stromal tumor, Carcinoma of unknown primary, Small bowel cancer

  3. Joselle M. Cook, M.B.B.S.

    Joselle M. Cook, M.B.B.S.

    1. Internist
    2. Oncologist
    3. Hematologist
    1. Rochester, MN
    擅长领域：

    Bispecific antibody therapy, Multiple myeloma

  4. Prashant Kapoor, M.D.

    Prashant Kapoor, M.D.

    1. Oncologist
    2. Hematologist
    1. Rochester, MN
    擅长领域：

    Bone marrow transplant, CAR-T cell therapy, Bispecific antibody therapy, Amyloidosis, Multiple myeloma, Waldenstrom mac...roglobulinemia

  5. Shaji Kumar, M.D.

    Shaji Kumar, M.D.

    1. Internist
    2. Hematologist
    1. Rochester, MN
    擅长领域：

    Bone marrow transplant, CAR-T cell therapy, Bispecific antibody therapy, Amyloidosis, Multiple myeloma

  6. Jason S. Starr, D.O.

    Jason S. Starr, D.O.

    1. Hematologist / Oncologist
    1. Jacksonville, FL
    擅长领域：

    Bispecific antibody therapy, Chemotherapy for colon cancer, Colon cancer, Liver cancer, Pancreatic cancer, Neuroendocri...ne tumor, Stomach cancer, Esophageal cancer, Pancreatic neuroendocrine tumor

  7. J.C. C. Villasboas Bisneto, M.D.

    J.C. C. Villasboas Bisneto, M.D.

    1. Internist
    2. Oncologist
    3. Hematologist
    1. Rochester, MN
    擅长领域：

    Bone marrow transplant, CAR-T cell therapy, Bispecific antibody therapy, Lymphoma, B-cell lymphoma, Follicular lymphoma

  8. Mojun Zhu, M.D.

    Mojun Zhu, M.D.

    1. Oncologist
    1. Phoenix, AZ
    擅长领域：

    Bispecific antibody therapy, Colon cancer, Hepatocellular carcinoma, Pancreatic cancer, Neuroendocrine tumor, Rectal ca...ncer, Stomach cancer, Cholangiocarcinoma, Esophageal cancer, Anal cancer, Small bowel cancer

研究

妙佑医疗国际 David F. 和 Margaret T. Grohne 癌症免疫学和免疫治疗研究项目的医生和科学家们正致力于推进前沿研究，以更好地了解免疫系统与癌细胞之间的相互作用。

妙佑医疗国际的医生正在积极开展临床试验，以开发使用双特异性抗体治疗癌症的新方法。其中包括将双特异性抗体与其他强效疗法联合使用，以及用基于双特异性抗体的新型疗法替代传统疗法。

妙佑医疗国际综合癌症中心符合美国国家癌症研究所综合癌症中心的严格标准。这些标准是对癌症预防、诊断和治疗方面的卓越科学成就和多专科诊疗模式的认可。

著述

请参阅美国国家医学图书馆检索服务系统 PubMed 所收录的妙佑医疗国际医生在双特异性抗体疗法领域的著述目录。

Research Profiles

来自妙佑医疗国际员工

在 Mayo Clinic 治疗

申请预约
关于在 Mayo Clinic 治疗
March 24, 2026
打印
  1. Klein C, et al. The present and future of bispecific antibodies for cancer therapy. Nature Reviews Drug Discovery. 2024; doi:10.1038/s41573-024-00896-6.
  2. Manis JP. Overview of therapeutic monoclonal antibodies. https://www.uptodate.com/contents/search. Accessed Sept. 30, 2025.
  3. Guidi L, et al. Bispecific antibodies in hematologic and solid tumors: Current landscape and therapeutic advances. American Society of Clinical Oncology Educational Book. 2025; doi:10.1200/EDBK-25-473148.
  4. Gu Y, et al. Clinical progresses and challenges of bispecific antibodies for the treatment of solid tumors. Molecular Diagnosis & Therapy. 2024; doi:10.1007/s40291-024-00734-w.
  5. Verma V, et al. Bispecific antibodies in clinical practice: Understanding recent advances and current place in cancer treatment landscape. Clinical and Experimental Medicine. 2025; doi:10.1007/s10238-024-01520-y.
  6. Jain MD, et al. Easy as ABC: Managing toxicities of antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies. ASCO Educational Book. 2025; doi:10.1200/EDBK-25-473916.
  7. Tan CR, et al. Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): An International Myeloma Working Group study. Blood Cancer Journal. 2025; doi:10.1038/s41408-025-01259-z.
  8. Choi SM, et al. Mechanism of action and pharmacokinetics of approved bispecific antibodies. Biomolecules & Therapeutics. 2024; doi:10.4062/biomolther.2024.146.
  9. Medical review (expert opinion). Mayo Clinic. Sept. 30, 2025.
  10. Tecvayli (prescribing information). Janssen Biotech; 2022 https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TECVAYLI-pi.pdf. Accessed Sept. 29, 2025.
  11. Imdelltra (prescribing information). Amgen; 2024. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Imdelltra/imdelltra_fpi.pdf. Accessed Oct. 1, 2025.
  12. Raje N, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel. Blood Cancer Journal. 2023; doi:10.1038/s41408-023-00879-7.
  13. Britto J, et al. Bispecific antibody toxicities. CMAJ. 2025; doi:10.1503/cmaj.241384.
  14. Morris EC, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews Immunology. 2022; doi:10.1038/s41577-021-00547-6.
  15. Derman B, et al. Real-world evidence evaluating teclistamab in patients with relapsed/refractory multiple myeloma: A systematic literature review. Cancers. 2025; doi:10.3390/cancers17071235.
  16. Health Education & Content Services. Staying connected with remote patient monitoring. Mayo Clinic; 2022.
  17. Altered immunocompetence. Centers for Disease Control and Prevention. https://www.cdc.gov/vaccines/hcp/imz-best-practices/altered-immunocompetence.html. Accessed Nov. 14, 2025.
  18. Rybrevant (prescribing information). Janssen Biotech; 2021. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  19. Blincyto (prescribing information). Amgen; 2014. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  20. Elrexfio (prescribing information). Pfizer; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  21. Hemlibra (prescribing information). Genentech; 2017. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  22. Epkinly (prescribing information). Genmab US; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  23. Vabysmo (prescribing information). Genentech; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  24. Lunsumio (prescribing information). Genentech; 2022. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  25. Kimmtrak (prescribing information). Immunocore; 2022. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  26. Haydu E, et al. The rules of T-cell engagement: Current state of CAR T cells and bispecific antibodies in B-cell lymphomas. Blood Advances. 2024; doi.org/10.1182/bloodadvances.2021004535.
  27. Columvi (prescribing information). Genentech; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 20, 2025.
  28. Talvey (prescribing information). Janssen Biotech; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 26, 2025.

相关

双特异性抗体疗法